Good day and thank you for standing by. Welcome to Galderma's conference call. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be the question and answer session with financial analysts. To ask a question during the session, analysts connected on the teleconference call will need to press star one one on your telephone keypad. You will hear an automatic message advising your hand is raised. To withdraw a question, please press star one one again. Please be advised that this conference is being recorded. I would now like to hand the conference over to Emil Ivanov, Head of Strategy, Investor Relations, and ESG, to introduce the call. Emil, please go ahead. Thank you very much. Welcome to Galderma 's 2025 third quarter trading update call. As customary, the press release was published at 7:00 A.M. Central European Standard Time today and can be viewed on our corporate website at any time. Today's presentation slides, as well as a recording of the webcast, will be made available on our website after the call. Please be advised that today's presentation contains forward-looking statements, which should be treated with the appropriate level of caution as advised on the slides. Let me now introduce today's trading update webcast. Dr. Flemming Ørnskov, CEO of Galderma, will provide performance highlights for the third quarter. Thomas Dittrich, CFO, will then present the trading update and the financial outlook for the full financial year. Both Flemming and Thomas will be available to answer questions from financial analysts before Flemming provides his final remarks to close the webcast. With this, I would like to invite Flemming to start with Galderma 's highlights for the third quarter of 2025. Flemming, over to you. Thank you, Emil. Good morning, good afternoon, and welcome to Galderma's third quarter 2025 trading update webcast. In a year of opportunities, we delivered record net sales for the first nine months, along with strong commercial and innovation momentum across our portfolio. For the first nine months, Galderma delivered $3.7 billion in net sales. These results are ahead of expectation, driven by focused execution of both the existing portfolio and new innovation. Growth was driven primarily by volume, complemented by a favorable mix. For the period, net sales growth was up 15% year-on-year at constant currency. Growth for the third quarter was up 21% year-on-year at constant currency. This represents an acceleration across all geographies and product categories, despite challenging market dynamics. The growth was especially strong for Nimluvio in the U.S., while newer modulators benefit from some favorable phasing in the third quarter. Based on our strong growth trajectory across the portfolio and Nimluvio's performance, we are raising our full-year guidance. For net sales growth, we expect to close the year between 17% and 17.7%. For core EBITDA, we expect a margin between 23.1% and 23.6%, both at constant currency. Our performance demonstrates our ability to deliver growth through commercial excellence, innovation, and global expansion. Let's look at some highlights by product category on the next slides. Galderma continues on its strong growth momentum with net sales growth acceleration in the third quarter across all product categories and geographies. Galderma achieved double-digit growth in both injectable aesthetics and therapeutic dermatology, reflecting broad-based growth momentum and successful commercial execution for the first nine months of the year. Dermatological skincare continued on a strong trajectory, specifically in international markets. Globally, all three product categories outperformed their respective markets. Both geographies delivered double-digit growth, as did most of Galderma's top 10 markets. Our performance reflects focused commercial execution across our core business, as well as incremental growth opportunities, as you'll see on the next slide. Let's start with injectable aesthetics, focusing on our newer modulator portfolio. Our next-generation neuromodulator, Relfydess continues to ramp up well in the 17 markets where it was already launched. Feedback remains very positive, and we are progressively gaining market share, mainly from competitors. I'm happy to share that we received three new approvals for Relfydess in Hong Kong, New Zealand, and the United Arab Emirates. This last one arrived just in time for us to showcase RelabotulinumtoxinA at the Aesthetic and Anti-Aging Medicine World Congress in Dubai. The congress took place in early October, and you can see some visuals on the right side of the slide. There was a lot of excitement. We look forward to the launch next year in a market where we currently do not have a neuromodulator offering. We also completed multiple additional Relfydess submissions globally, progressing in our plans to have the broadest neuromodulator portfolio globally. The neuromodulator subcategories overall have been performing really well, with market share gains in the U.S. and in international markets. If we focus on the European countries where Relfydess was launched, we see early signals demonstrating the strength of our neuromodulator portfolio strategy. Over the past 12 months, our neuromodulator portfolio gained 490 basis points of market share. In the third quarter, the portfolio delivered double-digit growth, with Dysport growing well and Relfydess continuing to ramp up. Moving now to fillers and biostimulators, where we continue to invest for growth. We gained further market share in fillers and biostimulators in international markets and in the U.S. Restylane continued to be impacted by a soft filler market, while Sculptra maintained a very strong growth trajectory with double-digit growth across geographies. I would like to showcase two specific efforts which are stimulating growth for this category. First, global activities on our proven injectable treatments for improving facial appearance after medication-driven weight loss. We believe that we're best positioned in this space with our clinically proven portfolio of Sculptra and the full Restylane range. We provide leading education and training for healthcare professionals, leveraging the first-of-its-kind clinical trial data focused on patients experiencing facial volume loss associated with a medication-driven weight loss. We also commissioned clinical consensus guidelines, which set a standard approach for identifying and managing the unique needs of this patient population. In the U.S., we launched a significant direct-to-consumer campaign called Sculpt and Lift, targeting patients on GLP-1 treatments. We believe this is an important opportunity to increase demand for the category and for the Galderma offering, as the campaign aims to bring medication-driven weight loss patients to aesthetic practices. This includes patients who may not have been aesthetic users before. Second, we continue to scale recently launched differentiated innovation. This includes the ramp-up of Restylane Shape in Brazil, which created a totally new segment. As a bone-mimicking filler, it offers an outcome which could previously only be achieved with invasive plastic surgery. The launch continues to progress strongly, with a positive halo effect on the rest of the portfolio of Restylane in the market. The other significant launch was Sculptra in China, which is on a very strong growth trajectory. Our Chinese team has been executing an exemplary on-the-launch strategy to increase awareness and penetration. Two of the achievements I find particularly impressive: over 100,000 units were sold in the first six months of the launch. Sculptra is already the number one search brand in biostimulator locally, with over 200 million impressions. Switching now to dermatological skincare, we continue to focus on the core of our business while also introducing new innovation to capture opportunities for further growth. Starting with Cetaphil, we further expanded its range to address white spaces. This included two totally transformative launches in the U.S., creating entirely new categories based on proven science. First, the Skin Activator Hydrating and Firming line. It marks an entirely new skincare category of advanced hydration and firming solutions, designed specifically to improve the appearance of aging, thinning, and fragile skin. This also marks our first step in strengthening our position in the faster-growing hands and body lotion segment, where we historically have been underrepresented in the U.S. Second, the Nourishing Oil-to-Foam Cleanser represents a breakthrough in hydrating cleansers for sensitive skin. This first-of-its-kind formula is designed to deeply cleanse while preserving hydration and supporting the sensitive skin's moisture barrier. As the essential first step in any skincare routine, it also removes sunscreen and makeup, making it ideal for double cleansing or as standalone use. In addition, Galderma continued to roll out recent innovation in international markets. This includes multiple Cetaphil lines, especially in the fast-growing Asian and Latin American markets. We're also using these to strengthen our position globally and capture local opportunities. For example, the gentle exfoliating SA line was launched in China, strengthening our offering in the face segment. For Alastin, the preferred peri-procedure skincare brand in the U.S., we broadened our reach and leveraged synergies with our injectable aesthetics portfolio. Following an exclusive launch for our partnering healthcare professionals, we initiated a broad consumer outreach for our restorative skin complex with next-generation Trihex technology. This has been another successful launch, turning the improved formula into one of Alastin's top-selling products. It also received Elle Magazine's Future of Beauty Award for top skin tightening cream, reinforcing its position for medication-driven weight loss patients. Second, we continue to expand Alastin in international markets. With the launch in China, we're excited about introducing Alastin to the second-largest precision-dispense market globally. Turning to therapeutic dermatology, Nimluvio remains on a strong trajectory, especially in the U.S. Nimluvio continues to surpass expectations, underpinned by growing demand and increased access. This is reflected in Nimluvio's growing share of total prescriptions and paid new patient stats. If we look at the six-week rolling average of paid new patient stats, also known as NBRX, from September to early October, Nimluvio was trending at about 37% market share in prurigo nodularis and 7.3% in atopic dermatitis. As a result, atopic dermatitis sales became the larger contributor in the third quarter. Overall, the majority of patients starting on Nimluvio were new, yes, new to advanced therapies. This demonstrates the value perceived from Nimluvio in these indications by healthcare professionals who have prescribed the product to their patients. Last, but of course not least, we continue to expand access for patients. The percentage of patients covered by commercial plans with broad access to reimbursement has surpassed 80%. For both indications, Nimluvio is reimbursed as a first-line biologic treatment with no need to first go through another therapy. Meanwhile, in international markets, Nimluvio's uptake continues to be strong in Germany. We have now launched Nimluvio in Austria, Switzerland, the United Kingdom, and Denmark, while progressing on price negotiations with multiple other markets where Nimluvio is already approved. A number of additional regulatory submissions globally are also in progress. As you can see, Galderma continues to perform strongly, advancing our growth drivers across the portfolio and reinforcing our leadership in dermatology through new data presentations and world-class education programs. I'd now like to hand over to Thomas to cover the sales performance in more detail, as well as the outlook for the remainder of the year. Thomas. Thank you, Flemming. It's my pleasure to comment on Galderma's Q3 2025 trading update and outlook, starting with an overview of net sales for the period. As mentioned by Flemming, Galderma continued on its strong momentum, achieving a record $3.737 billion in net sales for the first nine months of the year, up 15% year-on-year at constant currency. For the third quarter, this represented an acceleration to 21% year-on-year growth at constant currency. This was higher than expected for the quarter, based on strong performance across the portfolio and especially from Nimluvio's ramp-up, along with some favorable phasing in newer modulators. Growth was broad-based and continues to be driven by volume, complemented by a favorable mix, which more than offsets adverse price impacts. Looking now at injectable aesthetics, net sales were $1.871 billion, up 10.5% year-on-year at constant currency. Newer modulators' net sales were $1.053 billion, up 14.0% year-on-year at constant currency. Both the U.S. and international markets delivered double-digit growth, outperforming the market and gaining share. Growth was driven by strong performance of Dysport in both the U.S. and international markets, along with the ongoing ramp-up of RelabotulinumtoxinA. Newer modulator growth in the third quarter was 12.6% at constant currency, ahead of expectations, benefiting from strong execution, as well as some favorable phasing between the third and the fourth quarter. Fillers and biostimulators' net sales were $818 million, up 6.2% at constant currency for the first nine months. Again, Galderma grew faster than the market and gained share in both the U.S. and international markets. While fillers overall continue to be impacted by market softness, Galderma's performance was supported by the growth of differentiated products and especially new launches, including Restylane Shape in Brazil, as Flemming presented earlier. Biostimulators maintained very strong momentum with outstanding double-digit growth in both geographies. Sculptra remains our fastest-growing injectable aesthetics brand. Growth was especially high in the international markets, with widespread performance and strong contribution from China, where we just launched the brand earlier this year. Next, moving to dermatological skincare. Net sales for the first nine months were $1.063 billion, with year-on-year growth of 8.2% at constant currency. Galderma outgrew the market in dermatological skincare globally, with the majority of our key markets gaining share despite some constrained consumer spending. Growth in dermatological skincare was led by international markets, our larger geography, where both Cetaphil and Alastin grew double-digits. I would also be remiss not to mention Cetaphil's continued outstanding trajectory in fast-growing Asian markets, especially in India and China. In the U.S., performance was impacted by constrained consumer spending. Nonetheless, Cetaphil in the U.S. saw positive responses late in the third quarter from multiple promotional activities. Meanwhile, Alastin continued to deliver double-digit growth in the U.S. Now, onto therapeutic dermatology. Net sales reached $804 million for the first nine months of 2025, up 40.4% year-on-year at constant currency. Growth was driven by Nimluvio's continued outperformance, which more than offset the expected decline in the mature portfolio. Nimluvio's net sales for the first nine months were $263 million, predominantly from the U.S. and prurigo nodularis. However, atopic dermatitis, representing the larger market opportunity, overtook prurigo nodularis sales in the third quarter for the first time. As formulary coverage for patient reimbursement increased significantly, the results for the third quarter reflect managed care rebates resulting from securing commercial coverage. For the mature portfolio, excluding Nimluvio, performance was impacted by anticipated lower volumes and pricing pressures globally, especially in the U.S. Nonetheless, we also saw some positive momentum in international markets, where we capitalized on our strong portfolio in acne and rosacea. Now, looking at net sales geographically for the first nine months of the year, the majority of our top 10 markets grew double-digit, with particularly high performance in key international m,arkets, such as India, China, Mexico, Germany, and the U.K. and Ireland. Both reporting geographies accelerated their growth momentum, noting the U.S. growth was especially fueled by the Nimluvio ramp-up. International, which remains the larger of our two reporting geographies, continued its strong growth momentum with 13.2% net sales growth at constant currency. Injectable aesthetics delivered double-digit growth in most key international markets, including in Europe, Latin America, and Asia-Pacific. Both newer modulators and fillers and biostimulators grew double-digit, outpacing the market and gaining share. Newer modulators saw growth across markets. Flemming already shared some highlights for Europe, which delivered the greatest growth contribution supported by the launch of Dysport. Growth for newer modulators in the third quarter also benefited, as mentioned, by some favorable phasing relative to the fourth quarter. For fillers and biostimulators, Restylane gained share in most key markets, against a soft backdrop for fillers. As for Sculptra, we delivered strong growth and outstanding performance across international markets, with some markets growing even triple digits. This includes markets where Sculptra is already well established, especially in Latin America. Following the launch earlier this year, Sculptra continued its strong ramp-up in China, the second-largest injectable aesthetics market globally. Dermatological skincare also delivered double-digit growth internationally, ahead of the market, driven especially by continued outstanding growth of Cetaphil in Asia, especially in China and India. Alastin also contributed to strong growth from the ongoing international expansion, albeit from a smaller base. Therapeutic dermatology growth was primarily driven by the ongoing rollout of Nimluvio, also internationally. Moving now to the U.S., net sales growth was 17.5% year-on-year at constant currency. The growth contribution was particularly strong from the ramp-up of Nimluvio, while injectable aesthetics and dermatological skincare grew modestly. Both newer modulators and fillers and biostimulators outperformed the U.S. market and gained share. Growth was especially driven by Dysport and Sculptra, both growing double-digit, while Restylane outperformed a declining filler market. Dysport in the U.S. also benefited from some favorable phasing between the third and fourth quarter. In dermatological skincare, we navigated a constrained consumer spending environment in the U.S., especially impacting Cetaphil. Nevertheless, Cetaphil in the U.S. saw positive responses late in the third quarter from the multiple. If you're a participant, please stand by. If you're a participant, please continue to stand by. Apologies for the disruption. We are trying to resume the call. Bear with us. Thank you for that. Operator, could you please confirm that the sound is coming through? Yes, it is all loud and clear. Thank you. Perfect. Thomas, who resumed his remarks, is going to resume from his comments related to tariff exposure. Happy to do that. Now moving on to tariff exposure in terms of the U.S., our exposure to tariffs that are already in effect is deemed manageable. Tariffs are mainly relevant for our U.S. fillers and biostimulator portfolio, which represents approximately 7% of our total Galderma net sales. Please recall that any tariff would be on the import value, thus exposing only a portion of the in-market net sales price to tariffs. Furthermore, it is important to remember that our in-market net sales price charged to healthcare professionals is typically only the smaller portion of the end consumer treatment price. Also recall, more than 90% of all injectable aesthetics products currently sold in the U.S. are being imported. Our guidance fully factors in the exposure to all tariffs that are already in effect. Any further tariff announcements will be reviewed as to their potential impact during the remainder of the year, if any. Given the importance of the U.S. market, let me also remind you that we continue to expand our U.S. operations. Earlier this year, we announced our new U.S. headquarters in Miami, Florida, complementing our already established corporate and R&D hubs in three other U.S. states. We continue to provide significant healthcare professional education and training events across the country. We have committed to spend more than $650 million on U.S. manufacturing activities through third-party manufacturers over the next five years. This includes ramping up final assembly and packaging for Nimluvio in Florida, as well as the manufacturing of Alastin and select Cetaphil products with our contract manufacturing partners. Also, Galderma and its partners have initiated additional technology transfers to the U.S., focusing on key growth drivers, including double-sourcing Dysport in the U.S. Now on to guidance. We are raising our guidance for the full year, as Flemming already mentioned. This reflects our strong growth trajectory across the portfolio and especially of Nimluvio. We are raising net sales to 17.0%- 17.7% year-on-year growth at constant currency, from previously 12%- 14%. On core EBITDA, we are raising the margin range to 23.1%- 23.6% at constant currency, from previously approximately 23%. The guidance update especially reflects the significant ramp-up of Nimluvio, which is driving growth in therapeutic dermatology. It also reflects the strong trajectory in injectable aesthetics, with continued outperformance of the market in both newer modulators and fillers and biostimulators. In newer modulators, the fourth quarter is expected to be impacted by phasing effects. Full-year net sales growth for newer modulators is expected to be in the low teens at constant currency. At the half-year call, I translated low teens as 11% - 13%, as you recall. As we have now delivered a strong third-quarter growth rate, our full-year performance is largely de-risked, and we expect growth towards the upper end of this 11%- 13% growth range. In fillers and biostimulators, expectations for the fourth quarter are to maintain the recent growth momentum based on the strong trajectory of Sculptra and from new launches. Dermatological skincare is expected to accelerate its growth momentum to reach high single-digit growth at constant currency for the full year. Finally, for the therapeutic dermatology mature portfolio, the Q3 year-to-date performance is indicative of our expected full-year growth for this part of the business. The updated core EBITDA margin reflects reinvestments into growth for the group and to support Nimluvio's strong ramp-up. It also factors in the exposure to all U.S. tariffs that are currently in effect. Any further tariff announcements will be reviewed as to their potential impact during the remainder of the year. Please note that the updated guidance also has implications on the additional modeling metrics, which were previously provided in our Q3 financial results. In particular, the increased profitability is expected to positively impact the effective tax rate for the full year, putting it towards the lower end of the previously provided 23% - 25% range that we provided at the half-year call. This concludes the introductory remarks of Galderma's trading update for the third quarter of 2025. Before we close the meeting with Flemming's final remarks, I would like to now hand back to the operator to open the call for questions. In the interest of allowing sufficient time for all analysts to ask questions, I would kindly remind everyone to please limit your question to one each. Operator, can you please now open the line? Thank you so much. Dear analyst, if you would like to ask a question, please press star one one on your telephone keypad and wait for your name to be announced. To withdraw a question, please press star one and one again. Mr. Mbao will compile the Q&A roster. This will take a few moments. We are going to take up the first question. It comes from line of the Thibault Boutherin from Morgan Stanley. Your line is open. Please ask your question. Yes, thank you very much. A question is just on Nimluvio for the rest of the year. When we triangulate your comments on the business trends in Q4, it's clear to us that Nimluvio is the biggest moving part in the guidance. If you could just tell us where you see the most variability here, is it the uptake in atopic dermatitis in the U.S.? Is it the excess uptake? Any sort of help you can give us on where you see the moving parts for Nimluvio in Q4 would be helpful. Yeah, I don't know if I agree with your analytics, first of all. Thanks for the question. It's $263 million so far. You can see we have reported $3.737 billion. If I can do the math, that's not the majority. We had double-digit growth in injectable aesthetics. We had double-digit growth in therapeutic dermatology. We had 8.2% growth in dermatology skincare. I think we have to be a little bit careful not to think that this is about Nimluvio. Nimluvio is in a very early stage of its trajectory. It's performing or outperforming any benchmark we've set. We're at 7.2%, I think, share at this stage. If you look at NBRX for the AD market, and we're at 37. If you look at PN, we are now north of 80% commercial coverage. Next year, we'll enter most likely into the Medicare and Medicaid. We have a lot of other things that are growing incredibly fast. Nimluvio is important, but it's not the only thing. If I think about the contributions of Cetaphil internationally, if I think about the contribution already of RelabotulinumtoxinA, if I see the very strong performance of Dysport around the world, I think it was a little bit we need to moderate that sentiment. Any further questions, Thibault? Yeah, no, I mean, I think the question was just on the moving part in Q4 in particular, but that's fine. Thank you. We don't manage the company with just one company. We shift the resources, and I think we've seen we have brought growth in international and in the U.S., 17.5% growth in the U.S., 12%+ in international. If you look at the portfolio, it's almost all products that are showing incredibly strong growth, not just Nimluvio. Thank you. Thank you. Now we're going to take up our next question. The question comes to the line of Harry Sefton from UBS. Your line is open. Please ask your question. Brilliant. Thank you very much for taking the question. In fillers and biostimulators, we saw another strong quarter against a backdrop of a weak HA filler market. Should we think about the vast majority of that growth being driven by Sculptra? How should we think about the growth going into 2026 for Sculptra, given the push into GLP-1 patients? Do you think you'll be able to accelerate the growth for Sculptra next year? Also, thinking about Restylane growth going into next year, given the launch of skin boosters in the U.S. and a couple of other SKUs. Thank you. No, very insightful question. Thanks very much. Yeah, sometimes one gets lost in the minutiae details. If you take a step back, your strategic comment is totally right. Over time, in the combined category of fillers and biostimulators, Sculptra, the biostimulator part, is approaching half and will probably overtake it sometime next year. What we are seeing, but these are early signs, you should talk to all our competition. Is there a flattening on the negative trend with fillers? Yes or no? Your insights may be as good as ours. What we are seeing is that if you launch new and innovative fillers, like what we've seen with Restylane Shape, we have uptakes that match some of the best launches, like Restylane Kiss, Restylane Lift we've had. I think it's a bit of a mixed bag. There's pricing pressure, there's commoditization. If you bring innovation to the market, you see that. The unique advantage for us in one of the largest markets, we are going to be launching, I think, up to six new products, several of them being fillers, next year in the U.S., if all goes well. We're in the final stage of regulatory approvals for those. That should give us a boost. It is quite clear that the trend among consumers is, yes, we all want a newer modulator, and now we also want a biostimulatory product, and then we add on a filler. For treatment of some of the effects of significant weight loss with GLP-1s, you will need both a filler and biostimulatory product. It's early days to say how growth is driving. In certain parts of the world, if you go to the Middle East, it's a significant part i n the U.S., it's still early days. I would only add, when you ask about 2026, and we're not going to comment on 2026, Harry, but on the longer term, when you think about the biostimulator opportunity, remember we just launched in China, and the biostimulator opportunity longer term in China is so big, it's bigger than most the sizes of most injectable aesthetics markets in JPAC. That is where we just launched, and together with Flemming's comments, think of the longer term secular trend that we have here, and that's really big and amazing. That's brilliant. Thank you. Thank you. Now we're going to take our next question. Just give us a moment. The next question comes to the line of Shyam Kotadia from Goldman Sachs. Your line is open. Please ask your question. Hi, thank you for the question. A quick one on Nimluvio. In terms of the guidance going forward, you mentioned in the prior results that you're going to consider your greater than $2 billion peak sales guide for the drug. Given the ramp continues to be strong, do you have any update from that perspective? Also, any update in terms of the break-even assumptions, which I believe previously were 2027, and your assumptions hit blockbuster run rate was also 2027. Any update in regards to that would be super helpful. Thank you. Yeah, I don't think at this stage we're going to give guidance on Nimluvio, apart from what we've already said, it's $2 billion plus. When we look at the data, the uptake continues to be very strong. I think part of the success with the launch so far is we keep the head to the ground and we focus on building out the sales force, making sure we get access, making sure we do well against a very tough competitive set, and that we get as many doctors to experience the product so that they also can prescribe it to more patients. There's a lot of change going on. We used to be mainly dependent on PN. Now we see that AD is a larger part in the third quarter. That was the largest part. Net-net, of course, with this strong uptake, if it continues that way, we will at some point consider resetting the guidance for peak sales and, of course, also the profitability threshold guidance. Yeah, and on the profitability, let me just comment there on 2025, because this is the Q3 2025 call. Recall that we said that we expected, and in the H1 call, we expected the adverse P&L impact from Nimluvio launch investments and other investments to be 60% in H1 and 40% in H2. Let me update that here by saying that in H1, we have seen 75% of the adverse P&L impact, and it'll be only 25% in H2, driven by the strong uptake. Also remember, a strong uptake doesn't happen by itself. You need to reinvest some of those proceeds to make it happen in the follow-up period. That's what we have done very judiciously. Therefore, driving the strong uptake will bring the break-even point in, that's for sure, but we'll comment at a later stage when it's the appropriate time. We're on a very good trajectory here, as you see, also from a profitability standpoint. Sorry, it broke up a little bit when you said it'll bring the break-even point. Can you just repeat that last bit on the break-even point? It will bring the break-even point in because the strong uptake delivers additional profitability. We don't want to comment on that right now. We said it back today. It's sometime in 2027, so let's not get into any details. We will do that at the appropriate point in time. Thank you very much. Thank you. Now we're going to take our next question. The next question comes to the line of Benjamin Jackson from Jefferies. If your line is open, please ask your question. Great. Thank you for the question. One on Relfydess, if I may. I think you've spoken fairly positively about it for a number of quarters now in the ongoing launches. Is there perhaps any more depth in the color that you can provide to us, even around the relative size in terms of the entire neuromodulator number that you're putting out? Thinking about your strategy and how you launch it, is there more color you can provide about the uptake, but also how you balance the commercialization process between Dysport and Relfydess and then how that matters for the U.S. too? Thank you. Yeah, I think you have to take the background here. Since 2019, when we as a team took over, we have shown incredible growth of Dysport around the globe. Of course, we continue to support Dysport. It's an incredibly strong product. It competes well against Botox. We're launching it even in more and more countries. For us, that's the most important product we have right now. We're now launching another product. The way we've launched that is we know that in the neuromodulator space, there are still many things. One of them are the advance of. Certainly, we have a very good approach to the patient. We want to show our results to the other part of the people that we have made in the product. We've seen that the doctors and the health of the patient is very, very important. We're actually searching at the end of the time to make one of the other results we support all of our products and find different approaches. We have been focused on growing our offshore chip group. We've been doing one of the largest investments in the market in Europe. We're now going to launch in Australia. We're now going to work in Europe. Our current expansion of our investments and push our results to the truth, they will be maximized to our market. Everything will be possible. We can We can expect that later. I'm not sure I caught any like three-quarters of that due to the line breaking up. I don't know whether you could repeat it at all. Sorry about that. I'm not sure if it's just me. Sorry about that. Yeah. Sorry about that. We're really sorry about that. We seem to have some technical issues today. Your participants, please continue to stand by. Can you hear us? The speakers, please continue. Okay. Good. I apologize. Strong results, not so strong technical execution today. I apologize for that. Do you want me to repeat the answer? It was a bit long, but I'm happy to repeat it. Is that what you would like me to do? Please, that would be really useful if so. Thank you. I really apologize for these technical issues. What I was saying is that the way we since 2019 have basically been strengthening the commercial execution for Dysport, I think the way we've gained market share, in some cases, we've gained leadership. It's a very strong product. I think you see in most geographies, including the U.S., we've continued to gain significant market share also against Botox. When we had the opportunity to launch Relfydess initially in some European countries, the focus was, of course, to maintain the strong momentum of Dysport. We know that there's room for additional optionality among doctors and patients. Relfydess offers certain benefits, of course, fast onset. It's liquid duration. The doctors that have started using Relfydess, we see that they continue to have a strong preference for that. We still need to keep in mind that the vast majority of our sales today is Dysport. What our key strategy is to continue to drive our overall share of the neuromodulator market. Given we've now number one in Europe, number one in Australia, number one in Brazil, holding in in the U.S., I think the strategy is working. Remember, our play in injectable aesthetics is a portfolio play. We have multiple opportunities for you to use fillers under the Restylane name. We have Sculptra. Now, in many countries, we have two options for you if you want to use a neuromodulator. We think one of the core strengths of our gaining market share and honing in on leadership in aesthetics is because we have a broad portfolio approach. Thank you. Thank you for covering that over again. Thank you. Now we're going to take our next question. The question comes to the line of Yihan Li from Barclays. If your line is open, please ask your question. Hey, Yihan Li from Barclays. Congrats on the quarter, and thank you so much for taking our questions. I guess I have a question on Nimluvio treatment dynamics. I acknowledge Nimluvio launched still at a very early stage, but I'm still wondering, what is the average treatment duration so far in PN and also AD indications separately? Based on our research, it seems like the switch-out rate for Nimluvio remains at a very low level, but slightly increased a little bit in third quarter versus second quarter. Just curious, any observations on this discontinuation rate or like patient experiences so far? Thank you so much. Yeah, there's one advantage of being the CEO and a physician is that I interact with a lot of physicians. I just spent time yesterday with two of them. They both have a very large number of patients on the product, and I go together with my colleagues on many field visits. What you're observing is also what we hear back from the physicians and we're seeing in the market research. The dropout rate has been really low. We still see that every four weeks is the preferred duration, but we are now seeing that doctors and stable patients that have been itch-free, slept well at night, that they're now thinking about going or have already started to go to every eight weeks, which they see as a huge advantage. What we're seeing is that the initial feedback from patients and physicians has been reconfirming the fast itch relief. It's reconfirmed the very positive impact on sleep and quality of life. It also has been surprising for many physicians that they feel that the skin clearance is above what their expectations. They had strong expectations in PN, but maybe not so in AD, and they are in the patients they select to be on the product. The fact that we also can be used first line, the fact that we have a very large portion of our patients being biologic naive, it all probably speaks to the fact that for the moment, along with incredibly strong access, 80+% in commercial plans, we see low dropout rates. Of course, like any IO-13 and IO-31, it's not going to be for everyone. You know, the physicians have choices to make. The good news is a lot of physicians are starting to use Nimluvio as first line, given its safety profile, given what the fast itch relief, but it's way too early to comment on that. You know, we've just basically started to launch in certain parts of the world. We're building out the field force. We've just launched DTC. It's way too early at this stage to make big, bold projections on the brand. The other part that helps a lot is the tolerability. Flemming mentioned the lack of side effects, so to speak. The other part is just that it doesn't seem to sting as much because it's against the main competitor from a large French company. The volume is much, much lower. It's about a quarter. Therefore, the convenience of having to auto-inject yourself, and that's also practice that physicians tell us that helps people wanting to stay on the brand because it's just convenient. It's highly tolerable. It doesn't hurt as much. That's some of the learnings we're getting there, just complementing Flemming's comments. The most important is to realize, you know, we're on a journey. We're basically well into the launch of PN. We're basically now starting significantly the launch of AD. When you speak to physicians and what we see in market research, the ones that started to use Nimluvio, particularly in PN initially, they had a lineup of patients that had been difficult to treat for them with other products or that didn't want to jack. We probably got a pretty severe group of patients initially. Now we're moving into, I think, a broader group of patients and also first line in many cases. We'll see where that takes us. Thank you very much. Very helpful. Thank you. Now we're going to take our next question. Just give us a moment. The next question comes to the line of Victor Floc'h from BNP Paribas Exane. Your line is open. Please ask your question. Thanks a lot for taking my question, Victor Floc'h, BNP Paribas Exam. My question is on Relfydess, and I was wondering if you could comment on the timeline for securing the U.S. capacity and whether bringing this capacity online might shift your neuromodulators product mix further towards Relfydess, considering that the rest of your toxin portfolio is still expected to be manufactured out of the U.K. Thanks so much. No, our focus is still, and Epson is doing an excellent job, is to continue to manufacture in a reliable manner. In the history, we had some stockouts, but we've had a very good record now of delivery on time. That's very important because of the very strong growth rate that we're seeing. With Relfydess, we had a bit of subdued launch in Europe because we are new to the manufacturing of neuromodulators. We built a totally new manufacturing site in Sweden. We were a little bit cautious that we would not run out of stock, and we have not done that. We prioritize which countries we were launching in. The other thing that was very important and is still impacting a little about our launch trajectory for RelabotulinumtoxinA is we have to run a lot of batches to prepare for the filing of the complete response letter with the FDA. We have choices to be made all the time between making sure we have supply for the products where we are, the countries where we're also launched, and making sure we have batches enough for answering all the questions that we have to answer with the FDA. As I see right now, because remember, it's a lot of batches that have to be run and we have to do testing on these batches, everything seems to be going in the right direction. Whether it's going to be in December or flip into January, I do not know, but I think we're on track. Thank you. Thank you. Now we're going to take our next question. It comes to the line of Richard Vosser from JP Morgan. Your line is open. Please ask your question. Thanks very much for taking my question. A question on Dysport and the approval in the U.A.E. Obviously, as you said, Flemming, no presence there. I'm just thinking, how would you size the opportunity and how you would attack that opportunity in other areas where you don't have Dysport under your control and how we should think about the opportunity in those areas for Dysport? Thanks very much. The Middle East is a region that is near and dear to my heart as it is to our department because we go through a lot of challenges in that region. We had distributors in different markets and different countries. We set out on a venture, which was not an easy venture through arbitration and a whole case of some kind of lawsuit, but to try to ensure our ability to sell our products in the region. First, we've made really good progress with fillers, now with Sculptra. Now comes the next stage, which is with Dysport. We will be, you know, because Dysport is approved by the E.U., and now we can launch at the beginning of the year. It's a region that continues to surprise me. I recently was at a conference, AMWC, in Dubai. I heard that there'd be 3,000 people at the conference. I would think there were 6,000 people there. I saw the interest in Dysport, which we just got approved in time. I cannot quantify at this stage, but it also coincides with the fact that this is one of the regions where there's also very significant treatment for GLP-1. It's almost OTC. I think both what we're seeing for Sculptra and for fillers is very strong growth. I imagine now having the full armarium with Dysport should help us to secure more market share overall in injectable aesthetics. As you know, a lot of people from different parts of Europe are gravitating towards now also putting their clinics in U.A.E. The bigger market is, of course, KSA or Saudi. We see that as a great opportunity, but it's going to take a few rounds to get ready here and then we'll just have some substantial synergy in the next launch in the market. I'm optimistic about it, but it's going to take a bit of time. If I just add from a profitability standpoint, Dysport in the Middle East is super attractive because from the first unit onwards, it's royalty-free. We don't have to pay any royalties to Epson. That is also very attractive profitability-wise. It is, of course, as it ramps, then over time will be a contributor to our profitability margin expansion. Thank you very much. Very helpful. Thank you. We are going to take our last question for today. It comes to the line of Natalia Webster from RBC. Your line is open. Please ask your question. Hi there. Thanks for taking my question. It's just a follow-up on what you mentioned around Dysport and contribution to margins. Are you able to comment a bit more on when you expect this to be a meaningful driver to margins? Do we still need to see the U.S. approval and then those royalty caps to be reached in major markets for this? Thank you. Yeah, thank you, Natalia. Yeah, you're right. I mean, from an overall margin standpoint, think about what Flemming just said earlier. These ramps go slowly, steadily, but this is really sticky stuff. It ramps slowly, and remember, you'll never have a patent cliff either. You really want to do it the right way, that doctors like it, patients like it. They are in the driver's seat, the doctor's on the patient-doctor discussion. That's what it is. From a margin standpoint, I just said, look, there are some geographies like U.A.E and the Middle East that are royalty-free because we did not have the right to Dysport there. That's really attractive. There you have a contribution right from the get-go. In other territories in which we have the right to Dysport in various geographies, you have to hit certain levels. Really, in the U.S., once approved, given the size and the growth of the market, we would get to that threshold quicker than in the other territories where we have to pay royalties. There it takes a little bit longer. Overall, a very good trajectory. The excitement from patients seeing that fast onset and healthcare professionals' fast onset and the long duration, that's really what we should focus on. Profitability will follow, and it's very attractive for us. That will almost take care of itself. Thank you very much for the questions. Thank you, Thomas and Flemming, for the answers. I want to pass over to Flemming to give his final remarks so that we can close the webcast. First of all, thank you so much for your thoughtful questions and also for your patience. I think you'll recognize that we're good at commercial execution. Maybe we need to be a little bit better at meeting execution, but we always strive to improve. The good news was it happened on a day when we had strong results, so you couldn't accuse us of trying to hide something. As we highlighted today, we continue to be on a very strong trajectory, very focused execution, both on our existing portfolio and new innovation. I can hear from your questions you're very excited about a lot of new innovation, but don't forget, the vast majority of the growth is coming from our existing portfolio. We delivered $3.7 billion U.S. dollars for the first nine months. Record, growing 15% at constant currency. Widespread growth across product categories and geographies. Of course, you all honed in on Nimluvio, very strong growth in the U.S. We also have neuromodulators that also showed very strong growth. We also had some benefit from some phasing and full transparency. A lot of questions from you on U.S. tariffs. I think Thomas gave you a crystal clear answer. With what we see today, it's factored into the 2025 guidance, but it is a bit of a moving target. U.S., as you can see, is very important for us. Neuromodulators, Cetaphil, now Nimluvio. We also will invest significantly in the U.S., $650 million, as you may have read, U.S. dollars up to 2030, because we clearly need to increase our manufacturing footprint there. Given the importance of a number of products, Alastin, Nimluvio, and Cetaphil, that's a necessary investment. I think, as you've seen, strong growth trajectory, Nimluvio, strong performance. We've upped it full-year guidance, I think not by a small percent, but significantly both on top and bottom line. With that, again, thank you so much for your thoughtful questions today, and have a great rest of the day. This concludes today's conference call. Thank you for participating. We'll all disconnect. Have a nice day.